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Abstract
Heat shock protein 90 (HSP90) is involved in the regulation of diverse biological processes such as cell signaling,
proliferation and survival, and has been recently recognized as a potential target for cancer therapy. Ganetespib is a potent
ATP competitive inhibitor of HSP90. Ganetespib downregulated the expression of multiple signal transducing molecules
including EGFR, IGF-1R, c-Met, Akt, B-RAF and C-RAF, resulting in pronounced decrease in phosphorylation of Akt and Erk1/2
in a panel of five cutaneous melanoma cell lines including those harboring B-RAF and N-RAS mutations. Ganetespib
exhibited potent antiproliferative activity on all five of these cell lines, with IC50 values between 37.5 and 84 nM.
Importantly, Ganetespib is active on B-RAF mutated melanoma cells that have acquired resistance to B-RAF inhibition.
Ganetespib induced apoptosis and cell cycle arrest at G1 and/or G2/M phase. Ganetespib induced cell cycle arrest was
accompanied by altered expression of cyclin-dependent kinase inhibitor (CDKI) p21
Cip1 and p27
Kip1, cyclins B1, D1 and E,
and/or cyclin-dependent kinases 1, 2 and 4. HSP90 is functionally important for melanoma cells and HSP90 inhibitors such
as ganetespib could potentially be effective therapeutics for melanoma with various genetic mutations and acquired
resistance to B-RAF inhibition.
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Introduction
Heat shock protein 90 (HSP90) is a ubiquitous molecular
chaperone that promotes the conformational maturation and
stabilization of numerous client proteins. HSP90 is constitutively
expressed and can be upregulated during cellular stress [1].
Inhibition of HSP90 results in increased degradation of client
proteins via the ubiquitin proteasome pathway [2]. HSP90 is
involved in the regulation of diverse biological processes including
cell signaling, proliferation, and survival, as many HSP90 clients
are conformationally labile signaling molecules and recognized as
oncoproteins [2-4]. Interactions with client proteins enable HSP90
to promote cancer cell growth and survival by supporting
proliferative and/or anti-apoptotic mechanisms [2,5,6]. HSP90
has recently been recognized as a potential therapeutic target for
cancer, as accumulation of over-expressed and mutated client
proteins has been shown to promote a shift to the active and super-
chaperone complex form of HSP90 in cancer cells, conferring
a greater sensitivity of malignant cells to the loss of HSP90
function [7]. HSP90 as target for cancer therapy has potential
advantages. It may represent a relatively stable target for drug
treatment as no resistance mutations have been identified in this
molecule thus far [8]. HSP90 inhibition has the potential to affect
multiple signaling pathways that frequently contribute to the
tumor development and progression [2].
Ganetespib is a novel and potent HSP90 inhibitor binding to
the adenosine triphosphate (ATP)-binding domain of HSP90 [9].
It has been shown to induce degradation of multiple HSP90 client
proteins, kill a wide variety of human cancer cell lines at low
nanomolar concentrations in vitro, and exhibit potent anticancer
activity in xenograft tumor models in mice [9-12].
Melanoma is the fifth and sixth most common cancer in men
and women, respectively, in the United States [13]. Metastatic
melanoma is one of the most aggressive forms of skin cancer with
low response rate to standard chemotherapy and a median overall
survival less than one year [14]. While the response rate of patients
with BRAF V600E mutant metastatic melanoma to oral BRAF
inhibitor vemurafenib is high, the median overall survival is
approximately sixteen months [15]. The majority of the patients
who initially responded acquired resistance to vemurafenib within
months of initial treatment. Novel therapies are needed for
effective treatment of melanoma. Ganetespib has potent anti-
proliferative activity on a panel of cutaneous melanoma cell lines
through altering the expression of multiple regulators of growth
and survival signaling pathways, cell cycle and apoptosis. These
PLOS ONE | www.plosone.org 1 February 2013 | Volume 8 | Issue 2 | e56134alterations ultimately result in cell cycle arrest and apoptosis in
melanoma cells.
Results
Ganetespib Downregulates Multiple Signaling Pathways
in Melanoma Cells
We investigated the effect of ganetespib on signaling molecules
that have been reported to be the clients of HSP90, including c-
Met, EGFR, and IGF-1R [2,16,17], in a panel of five melanoma
cell lines (Figure 1A). Cell lines K028 and K029 harbor B-RAF
V600E mutation while K033 and M23 carry N-RAS Q61R
mutation. Cell line K008 is wild type for B-RAF and N-RAS. In
agreement with our previous observations [18], melanoma cell
lines express varying levels of EGFR, c-Met, and IGF-1Rb. EGFR
was expressed in K008, K028, M23 and K033 cells and
downregulated after ganetespib treatment. c-Met expression was
detected in K008, K028 and K033 cells and was decreased by
ganetespib. IGF-1R was expressed in all melanoma cell lines and
reduced by ganetespib. The effect of ganetespib on EGFR in K029
cells and c-Met in K029 and M23 cells remained unclear due to
very low abundance of these receptors in these cells. We examined
the effect of ganetespib on the expression of phosphorylated
EGFR, c-Met and IGF-1R in K008 and K028 cells that express all
three receptors. In line with decreased expression of these
receptors, the levels of phosphorylated EGFR, c-Met and IGF-
1R were reduced in ganetespib treated cells (data not shown). Akt
was minimally decreased after 24 hours of ganetespib treatment
(Figure 1A), but was substantially reduced after 48 h treatment
(Figure 1B), in agreement with being a client protein of HSP90
[19]. Akt phosphorylation was decreased in all cell lines after
ganetespib treatment for 24 h except it was increased in K028 cells
treated with 100 nM ganetespib (Figure 1A). Erk1/2 phosphor-
ylation was markedly inhibited in all cell lines while total Erk1/2
levels remained unaltered (Figure 1A).
Ganetespib Decreases Viability of Melanoma Cells
We next tested the cytotoxic effect of ganetespib on K008,
K028, K029, M23 and K033 melanoma cells. Ganetespib
effectively decreased viability of all five cell lines (Figure 2A).
Maximum viability reduction, ranging from 60 to 90%, was
achieved with 100 nM ganetespib. The IC50 values of ganetespib
on these cell lines are 37.5 - 84 nM (Figure 2B).
Ganetespib Induces Cell Cycle Arrest in Melanoma Cell
Lines
In order to better understand the antiproliferative action of
ganetespib on melanoma cells, we examined its effect on cell cycle
progression. Treatment with 250 nM ganetespib for 24 hours
resulted in cell cycle arrest at varying phases (Figure 3A).
Substantial G2 arrest was observed in K008 and K028 cells, G1
arrest in K029 cells, and G1 and G2/M arrest in M23 cells
(Figure 3B). A modest increase in G1 population was also seen in
ganetespib treated K033 cells.
Effect of Ganetespib on Cell Cycle Regulators
To better understand the molecular mechanisms by which
ganetespib induced cell cycle arrest, we examined the expression
of negative and positive cell cycle regulators in melanoma cells
treated with ganetespib for 48 hours (Figure 3C). The expression
of cyclin-dependent kinase inhibitor (CDKI) p27
Kip1 was increased
in K029, M23 and K033 cells. An increase in p27
Kip1 was also
detected in K028 cells treated with 100 nM ganetespib. The
expression of p21
Cip1 was elevated in K008 and K028 cells and in
K029 cells treated with 100 nM ganetespib while it was reduced in
K033 cells. The expression of p21
Cip1 in M23 cells was below
detectable levels. Cyclin D1 expression was reduced in K008,
K029 and M23 cells and to a lesser extent in K033 cells treated
with 100 and 250 nM ganetespib. Cyclin E was decreased in
K008, M23 and K033 cells. A modest decrease in cyclin E was
also seen in K028 and in K029 cells treated with 250 and 500 nM
Figure 1. Downregulation of multiple signaling pathways by ganetespib in melanoma cells. A. Cells were treated with indicated amounts
of ganetespib for 24 h. B-RAF and N-RAS mutational status of each cell line is indicated. B. Cells were treated with 250 nM ganetespib for 48 and 72 h.
Proteins levels were determined by Western blot analysis.
doi:10.1371/journal.pone.0056134.g001
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cells treated with 250 and 500 nM ganetespib while it was reduced
in K029 and K033 cells and in K028 and M23 cells treated with
100 nM ganetespib. The expression of CDK1 was significantly
reduced in K008, K028, M23 and K033 cells and to a lesser
extent in K029 cells. The expression of CDK2 was reduced in
K008, K028 and K033 cells and in M23 cells treated with 100 nm
ganetespib. CDK4 was significantly reduced in K008, K029, M23
and K033 cells and modestly decreased in K028 cells.
Figure 2. Antiproliferative action of ganetespib on melanoma cells. A. Ganetespib reduced viability. Cells were treated with varying amounts
of ganetespib for 72 h and subjected to MTS assay. Data are expressed as mean6SD of three independent experiments. B. Mutational status and
ganetespib IC50 of cell lines.
doi:10.1371/journal.pone.0056134.g002
Figure 3. Ganetespib induced cell cycle arrest in melanoma cells. A. Cells were treated with 250 nM ganetespib for 24 hours, stained with PI
and subjected to FACS analysis. B. Bar graphs of percentage of G1, S, and G2/M populations in control and ganetespib treated cells. C. Alterations in
expression of multiple cell cycle regulating proteins induced by ganetespib. Cells were treated with indicated amounts of ganetespib for 48 h and
analyzed by Western blot analysis. Relative expression levels of proteins (treated vs. control cells) are indicated.
doi:10.1371/journal.pone.0056134.g003
HSP Inhibition in Melanoma
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Annexin V staining analysis revealed that ganetespib treatment
significantly induced apoptosis in K008, K028, K029, M23 and
K033 cells (Figure 4A). In agreement, ganetespib treatment
resulted in PARP cleavage in all cell lines and caspase-3 cleavage
in K033 cells (Figure 4B). Modest decrease in pro-caspase-3 levels
was also seen in K028 and K029 cells (Figures 4B), although
cleaved casapase-3 was not detected in these cell lines.
Effect of Ganetespib on Anti-apoptotic Proteins
As ganetespib significantly induced apoptosis in melanoma cells,
we next investigated the response of antiapoptotic proteins to
ganetespib. Survivin was reduced in K029 and K033 cells, but
induced in K008 and K028 cells (Figure 4C). Bcl-2 was decreased
in K033 cells while it was increased in the rest of cell lines. Bcl-xL
levels were elevated in K028, K029 and M23 cells but decreased
in K033 cells while remained unaltered in K008 cells. Mcl-1 was
decreased in K008 cells, increased in M23 and K033 cells, and
unaltered in K028 and K029 cells.
Effect of Ganetespib on B-RAF, C-RAF and N-RAS
Oncogenic B-RAF and N-RAS mutations have been detected in
approximately 60% and 20% of cutaneous melanoma respectively
[20-24]. While B-RAF inhibition is initially effective for melanoma
carrying a B-RAF mutation, resistance to B-RAF inhibition
develops within months after start of treatment [25,26]. MAPK/
Erk1/2 activation via C-RAF overexpression and upregulation of
RTKs (PDGFRb and IGF-1R) or N-RAS mutation have been
reported to be among the mechanisms by which melanoma cells
acquire resistance to B-RAF inhibitors [27-29]. Therefore, we
examined whether ganetespib affected the expression of B-RAF,
C-RAF and N-RAS in melanoma cells. Treatment with 100 and
250 nM ganetespib resulted in marked downregulation of wild
type and mutant B-RAF and C-RAF expression in all 5 melanoma
cells lines tested (Figure 5). In comparison, ganetespib increased N-
RAS expression in three N-RAS wild type cell lines (K008, K028
and K029) and one N-RAS mutated cell line (M23) and modestly
decreased N-RAS expression in one N-RAS mutated cell line
(K033) (Figure 5).
Ganetespib Effectively Reduces Viability of Melanoma
Cells with Acquired Resistance to B-RAF Inhibition
Currently, there is no effective treatment for melanoma with
acquired resistance to B-RAF inhibition. We investigated whether
ganetespib exhibited antiproliferative action on melanoma cells
with acquired resistance to B-RAF inhibition. GDC-0879 is a B-
RAF mutant specific inhibitor and has been shown to inhibit the
growth of melanoma cells harboring B-RAF mutations [30]. As
expected, GDC-0879 exerted pronounced antiproliferative activity
to K029 cells at nanomolar concentrations (Figure 6A). After
subjection to chronic treatment with GDC-0879, K029 cells
developed resistance to GDC-0879 (Figure 6A). However, the
viability of K029 cells with acquired resistance to GDC-0879
(K029GDCr cells) were reduced by ganetespib to similar levels as
Figure 4. Ganetespib induced apoptosis in melanoma cells. Cells were treated with 100 nM ganetespib for 72 hours. A. Apoptotic cells were
detected using Annexin V-FITC staining and FACS analysis. B. Cleavage of PARP and casapase-3. C. Effect of ganetespib on the expression of
antiapoptotic proteins. Cells were treated with ganetespib for 48 h and analyzed using Western blot analysis. Relative expression levels of proteins
are indicated.
doi:10.1371/journal.pone.0056134.g004
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associated with increased expression of B-RAF, C-RAF, and
Erk1/2 activity (Figure 6C) in agreement with previous findings
[27-29]. Ganetespib decreased the expression of B-RAF, C-RAF,
and phosphorylation of Akt and Erk1/2 (Figure 6C).
Discussion
The HSP90 inhibitor ganetespib, with IC50 values ,100 nM,
exhibited profound antiproliferative activity against a panel of
cutaneous melanoma cells including those that carry B-RAF and
N-RAS mutations, as well as those with acquired resistance to B-
RAF inhibition. Ganetespib exerted its antiproliferative activity
through induction of cell cycle arrest and apoptosis in association
with inhibition of multiple tyrosine receptor kinases, B-RAF, C-
RAF, and the AKT and Erk1/2 pathways.
The PI3K/Akt and MAPK/Erk pathways are critical for
melanoma cell growth and survival [31,32] and were significantly
inhibited by ganetespib. During the course of this study, similar
effects of the HSP90 inhibitor XL888 on phosphorylation of Akt
and Erk1/2 in melanoma cells have been reported [33]. Inhibition
of these pathways may contribute to ganetespib induced growth
inhibition and apoptosis as inhibition of these pathways, alone or
in combination, reduced viability of K008 and K028 cells (data
not shown) and induced apoptosis in melanoma cells [33]. In
agreement with previous findings that Akt but not Erk1/2 was
a client protein of HSP90 [19,34], the expression of Akt but not
Erk1/2 was reduced by ganetespib. Ganetespib may inhibit Akt
phosphorylation through downregulating Akt expression and
repress Erk1/2 phosphorylation through downregulating their
upstream activating kinases (MEK and MEKK1), as MEK and
MEKK1 are client proteins of HSP90 [35,36]. Akt and Erk1/2
can be activated by signals from multiple tyrosine kinase receptors
including EGFR, IGF-1R and c-Met [37]. In agreement with
being client proteins of HSP90 [2,16,17,38], the expression of
Figure 5. Effect of ganetespib on B-RAF, C-RAF and N-RAS expression in melanoma cells. Cells were treated with indicated amounts of
ganetespib for 48 h and subjected to Western blot analysis.
doi:10.1371/journal.pone.0056134.g005
Figure 6. Ganetespib reduced viability of K029 cells with acquired resistance to B-RAF inhibition as effectively as the parental cells.
A. Chronic treatment of K029 cells with B-RAF inhibitor GDC-0879 resulted in resistance to B-RAF inhibition. K029 cells and GDC-0879 resistant K029
cells (K029GDCr) were treated with varying amounts of GDC-0879 for 3 days and subjected to MTS assay. B. Ganetespib reduced viability of K029GDCr
cells as effectively as K029 cells. K029GDCr (in the presence of 1 mM GDC-0879) and K029 cells were treated with ganetespib for 3 days and subjected
to MTS assay. C. Ganetespib downregulated the expression of B-RAF, C-RAF, phosphorylated Akt and Erk1/2 in K029 and K029GDCr cells. Cells were
treated with indicated amounts of ganetespib for 48 h and proteins were determined by Western blot analysis.
doi:10.1371/journal.pone.0056134.g006
HSP Inhibition in Melanoma
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these receptors will also result in inhibition of Akt and Erk1/2
phosphorylation. Thus, ganetespib may inhibit Akt and Erk1/2
activation by targeting multiple cellular signaling processes. Small
molecule inhibitors of c-Met, EGFR or IGF-1R reduced viability
of K008 and K028 cells that express all these receptors (un-
published data), suggesting that these receptor tyrosine kinases
may play a role in survival and growth of these cell lines and their
inhibition may be relevant to the anti-melanoma activity of
ganetespib.
Ganetespib induced cell cycle arrest at G1and/or G2/M phase
in cell line dependent manner. Similar cell cycle effects were also
observed with XL888 [33]. Ganetespib induced cell cycle arrest
was associated with upregulation of negative cell cycle regulators
(p21
Cip1 and/or p27
Kip1) and/or downregulation of positive
regulators (cyclins D1 and E, CDK1, CDK2 and CDK4). This
is in general in line with the roles of these regulators in cell cycle
regulation [39,40]. CDK1, CDK2 and CDK4 have been reported
to be chaperoned by HSP90 [17,41-43]. However, cyclin D1 and
cyclin E are not considered to be a client protein for HSP90. The
observed downregulation of cyclin D1 may result from down-
regulation of Akt and Erk1/2 pathways, which control cyclin D1
expression [44,45]. Downregulation of cyclin E could result from
decreased D-type cyclins, as the transcriptional activation of the
cyclin E gene depends on the activity of D-type cyclins [46]. The
upregulation of the CDK inhibitors p27
Kip1 and p21
Cip1 could be
attributed to inhibition of the Akt and Erk pathways [40,47-49].
Despite being reported to be a client protein of HSP90 [50] and
downregulated in K029 and K033 cells, cyclin B1 was induced by
ganetespib in two cell lines (K008 and M23) that were arrested at
G2/M. Cyclin B1 activity is essential for progression from G2 into
M phase. Binding of cyclin B1 to CDK1 allows CDK1 to be
activated [51,52]. The active cyclin B1-CDK1 complex translo-
cates to the nucleus and phosphorylates nuclear substrates. These
phosphorylation events are necessary for mitotic onset. The
accumulation of cyclin B1 may allow these cells to progress
through G1 and S phase and enter G2 phase. On the other hand,
CDK1 was downregulated by ganetespib in all three cell lines
(K008, K028 and M23) that were arrested at G2/M phase. In
addition, p21
CIP1 was upregulated in K008 and K028 cells and
p27
KIP1 was upregulated in M23 cells. Both p21
Cip1 and p27
Kip1
can block G2/M transition by direct interaction with B1 and block
cyclin B1-associated kinase activities [52,53]. These findings
suggest that ganetespib may induce G2/M arrest by down-
regulating CDK1 in combination with accumulation of p21
CIP1 or
p27
Kip1.
Ganetespib substantially induced apoptosis in all melanoma cell
lines tested here. Although the common anti-apoptotic proteins
survivin, Bcl-2, and Bcl-xL have been reported to be client
proteins of HSP90 [18,54,55], they were, surprisingly, not altered
or even induced by ganetespib in most of the cell lines. Similar
response to ganetespib was also observed with antiapoptotic
protein Mcl-1. Ganetespib only decreased the expression of
survivin in K029 and K033 cells, Bcl-2 and Bcl-xL in K033 cells,
and Mcl-1 in K008 cells. It is widely believed that inhibition of
Hsp90 with small molecule inhibitors can disrupt the physical
binding of survivin to Hsp90, leading to survivin downregulation
[54]. However, we showed here that survivin protein levels were
increased in K008 and K028 cells treated with ganetespib.
Although the molecular events for this increase is not clear, it has
been reported that survivin expression was induced by HSP90
inhibitors in some cancer cell lines via cell context dependent
transcriptional, translational and/or post-translational (such as
26S proteasome-mediated protein degradation) mechanisms [56].
These findings suggest that ganetespib-induced apoptosis is largely
attributed to altered expression of other pro- and/or anti-
apoptotic proteins that remain to be identified. Ganetespib
induced upregulation of p27
Kip1 may play a role in apoptosis
induction as p27
Kip1 has been shown to induce apoptosis [57-59].
The proapoptotic BIM proteins have also been recently shown to
be induced by XL888 and play a role in XL888 induced apoptosis
in melanoma cells [33].
Ganetespib profoundly inhibited the growth of melanoma cells
harboring wild type and mutated B-RAF or N-RAS. B-RAF and
N-RAS mutations play a key role in the development of human
melanomas [20-22]. B-RAF mutations have been found in
approximately 50% of human melanomas with V600E being the
most common mutation [20]. B-RAF V600E stimulates constitu-
tive activation of MEK/Erk/12 pathway, resulting in growth
factor independent proliferation [21-23]. In agreement with being
clients of HSP90 [60-62], the expression of both wild-type and
mutant B-RAF was decreased by ganetespib in all melanoma cell
lines including those cells with acquired resistance to B-RAF
inhibition. Similar to B-RAF, the expression of C-RAF was
reduced in ganetespib treated cells. Downregulation of B-RAF and
C-RAF contributes to inhibition of Erk1/2 phosphorylation and
the growth of melanoma cells including those with acquired
resistance to B-RAF inhibition. Interestingly, although ganetespib
exerted antiproliferative activity towards melanoma cells harbor-
ing mutated N-RAS, N-RAS was induced by ganetespib in most of
the cell lines tested. To the best of our knowledge, N-RAS has not
been shown to be a client of HSP90.
In melanoma cells carrying the B-RAF mutations, activation
through B-RAF and subsequent downstream signaling is the major
driving force for tumor progression, making B-RAF an attractive
target for anti-melanoma therapy. Clinical data has shown that
treatment with B-RAF inhibitor vemurafenib resulted in tumor
shrinkage and median progression-free survival for greater than six
months in patients with B-RAF V600E mutated melanoma [25].
However, the majority of the patients who initially responded
developed resistance to vemurafenib. MAPK/Erk1/2 activation
via C-RAF overexpression and upregulation of RTKs (PDGFRb
and IGF-1R) or N-RAS mutation are among the mechanisms for
acquired resistance to B-RAF inhibition [27-29]. Ganetespib
inhibited the growth of melanoma cells with acquired resistance to
B-RAF inhibition as effectively as the parental cells. Similar
findings have recently reported with HSP90 inhibition with
XL888 [33]. These findings suggest that ganetespib may
potentially be used for patients with melanoma resistant to B-
RAF inhibition. Ganetespib may prevent melanoma cells from
acquiring resistance to B-RAF inhibition by targeting multiple
signal pathways and kinases important for development of
resistance to B-RAF inhibitors.
The present study has its limitations. For example, the data
presented were obtained using in vitro models of melanoma and
in vivo studies to examine anti-melanoma activity of ganetespib
are important. Furthermore, the molecular responses of melanoma
cells to ganetespib and the mechanisms by which ganetespib
induced cell cycle arrest and apoptosis have not been fully
investigated. Nonetheless, our data show that ganetespib exerts
potent antiproliferative activity against a panel of melanoma cell
lines including those with common activating mutations. In-
hibition of HSP90 function by ganetespib produced complex
molecular effects in melanoma cells. Some of the molecular effects
of HSP90 inhibition were similar among the melanoma cell lines
tested. This is exemplified by downregulation of c-Met, IGF-1R,
EGFR, Akt, phosphorylation of Akt and Erk1/2, suppression of
positive cell cycle regulators and/or upregulation of negative cell
HSP Inhibition in Melanoma
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into a similar pattern of biologic consequences such as cell cycle
arrest and apoptosis. However, the degree of these effects varied
among the cell lines. Furthermore, distinct effects of ganetespib on
the expression of some cell cycle and apoptosis regulatory proteins
were observed among the cell lines. These findings reflect tumor
heterogeneity and may influence the phase and degree of cell cycle
arrest and death. These complex effects of HSP90 inhibition may
provide optimal anti-tumor activity and prevent further de-
velopment of resistance. These findings underscore the therapeutic
potential of HSP90 inhibitors such as ganetespib for melanoma.
Materials and Methods
Cell Lines
Cutaneous melanoma cell lines K008, K028, K029, K033 and
M23 were established from harvested fresh tissues that underwent
mechanical and enzymatic digestion and in vitro expansion. Tumor
samples were obtained from patients on Dana-Farber/Harvard
Cancer Center Institutional Review Board approved protocols
with written informed consent for the original human work that
produced the tissue samples. Cutaneous melanoma cells were
grown in DMEM containing 10% FBS, 50 mg/ml penicillin and
100 mg/ml streptomycin.
Viability Assay
Cells were seeded in 96-well plates at 2x10
3 cells per well and
incubated over night followed by treatment with varying amount
of Ganetespib (provided by Synta Pharmaceuticals Corp.) for
72 h. Cell viability was determined using MTS assay per
manufacturer instructions (Promega, Madison, WI).
Cell Cycle and Apoptosis Analysis
After treatment with Ganetespib, cells were harvested by
trypsinization and analyzed for cell cycle distribution and
apoptosis as previously described [18]. For cell cycle analysis,
cells were fixed in ethanol, stained with propidium iodide in PBS
containing Triton X-100 (0.1%) and RNase A (0.2 mg/ml) for
30 min, and then subjected to FACS analysis. For apoptosis
analysis, cells were incubated with FITC-Annexin V in 1x
Annexin Binding buffer (BD Bioscience, San Joes, CA) for
15 min and subjected to FACS analysis. Cell cycle distribution
and percentage of apoptotic cells were estimated using ModFit and
Flowjo software respectively.
Immunoblot Analysis
Whole cell lysate preparation and immunoblot analysis were
performed as described previously [18]. Antibodies against EGFR,
c-Met, IGF-1R, Akt, phospho-Akt, Erk1/2, phospho-Erk1/2,
cyclin D1, cyclin B1, Bcl-2, Bcl-xL, survivin, CDK2 and C-RAF
were purchased from Cell Signaling Technology (Danvers, MA).
Antibodies against P27
Kip1, p21
Cip1, CDK1, CDK4, cyclin E, B-
RAF were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). N-RAS antibody was purchased from Millipore
(Billerica, MA). Actin antibody was purchased from Sigma-Aldrich
(St. Louis, MI). Density of protein bands was measured using NIH
ImageJ software and normalized to that of actin.
Establishment of Melanoma Cells Resistant to B-RAF
Inhibition
K029 cells were treated with gradually increasing amounts (0.1,
0.2, 0.5, 1, 5 and 10 mM) of B-RAF V600E specific inhibitor
GDC-0879 through ,3 months until they were resistant to 10 mM
of the drug. GDC-0879 was purchased from Selleck Chemicals
(Houston, TX).
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